Thymosin Beta-4 Fragment

Thymosin Beta-4 Fragment is a naturally occurring peptide derivative that functions as an investigational therapeutic agent with anti-inflammatory, pro-angiogenic, and tissue-regenerative properties, primarily targeting wound healing and fibrosis reduction.

Brief glance

The primary outcome is Recovery & Repair, but it's also used for Immune Support. This compound is considered a Peptide. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.

Overview

Thymosin Beta-4 Fragment is a truncated derivative of the regenerative peptide Thymosin Beta-4, retaining select bioactive domains for cytoprotection, anti-inflammatory effects, and tissue remodeling without full actin-binding activity. Specific fragments like 1-15 exhibit anti-apoptotic and neuroprotective properties in models of brain injury and ischemia, while 1-4 targets NF-κB and TGF-β1 pathways to reduce fibrosis in hepatic, pulmonary, and cardiac tissues. These fragments support potential clinical roles in wound healing, corneal repair, and organ protection, akin to the parent peptide's applications in ulcers and soft tissue injuries.

Thymosin Beta-4 Fragment refers to bioactive peptide segments derived from the full-length thymosin beta-4 (Tβ4) molecule, a naturally occurring 43-amino acid peptide found in most cell types throughout the body. The most clinically studied fragments include the N-terminal tetrapeptide Ac-SDKP (amino acids 1–4), which exhibits pronounced anti-inflammatory and anti-fibrotic properties by modulating nuclear factor-κB (NF-κB) and transforming growth factor-β1 (TGF-β1) signaling pathways, and the 1–15 fragment, which provides cytoprotective and anti-apoptotic effects through mitochondrial and transcriptional mechanisms. These fragments are investigated for therapeutic applications in chronic inflammatory conditions, organ fibrosis (hepatic, pulmonary, cardiac, and renal), wound healing, and tissue regeneration, as they retain selective biological activity while lacking certain domains of the parent peptide. The pharmaceutical interest in Thymosin Beta-4 Fragment stems from its tissue-independent mechanisms of action and its potential to modulate immune dysregulation and pathological tissue remodeling without the broader cellular effects of the complete molecule.

Benefits

Thymosin Beta-4 Fragment accelerates wound healing by promoting keratinocyte and fibroblast migration to injury sites, with clinical studies demonstrating improved outcomes in chronic wounds and corneal injuries.¹,²,³ It exhibits anti-inflammatory effects by inhibiting pro-inflammatory cytokines like TNF-alpha and IL-1beta, alongside antifibrotic actions that reduce myofibroblast differentiation and excessive collagen production, particularly in cardiac and renal fibrosis.¹,⁴ Preclinical and early clinical evidence supports its role in cardiac regeneration post-myocardial infarction through enhanced angiogenesis and cardiomyocyte repair, as well as potential applications in ophthalmology for dry eye and corneal conditions.¹,²,⁵

Side effects

Thymosin Beta-4 Fragment, as a peptide active pharmaceutical ingredient derived from the parent Thymosin Beta-4 (TB4), is under investigation for its roles in cytoprotection, anti-inflammatory effects, anti-fibrotic activity, and tissue regeneration, particularly in preclinical models of ischemia, fibrosis, and neurodegeneration.⁶ Common side effects associated with TB4 and its fragments include mild injection site reactions such as redness, swelling, pain, or irritation, along with transient gastrointestinal discomfort, headaches, dizziness, lethargy, and fatigue.⁷,⁸,⁹ Rare but more serious adverse effects may involve fever, blistering at the injection site, muscle aches, skin rash, severe itching, hives, or vomiting, in which case discontinuation and medical consultation are advised.⁸ Key safety considerations include using only pharmaceutical-grade material prescribed by a physician, starting at lower doses with gradual titration, rotating injection sites, maintaining hydration, and cycling use (e.g., no more than 3 months continuously) to minimize risks, as safety in pediatrics is not established and long-term data remains limited.⁸,¹⁰ Theoretical concerns from TB4 research include potential promotion of tumor metastasis due to anti-apoptotic properties, warranting caution in patients with malignancy.⁷

Mechanisms of action

Thymosin Beta-4 Fragment refers to enzymatically cleaved shorter sequences from the full-length 43-amino acid Thymosin Beta-4 (Tβ4) peptide, such as Tβ4(1-15) or the N-terminal Tβ4(1-4) known as Ac-SDKP, which exhibit targeted bioactivities distinct from the parent molecule.¹,⁶,¹¹ These fragments primarily modulate cytoskeletal dynamics by binding monomeric G-actin, thereby regulating actin polymerization, cell migration, and tissue remodeling processes.¹,⁶,¹² For instance, the Tβ4(1-15) fragment promotes cell survival by suppressing pro-apoptotic mediators like Bax, upregulating Bcl-2, and enhancing antioxidant pathways via FoxO3a and Nrf2 to mitigate oxidative stress and apoptosis.⁶ Meanwhile, the Ac-SDKP fragment (Tβ4(1-4)) exerts anti-inflammatory and anti-fibrotic effects by inhibiting NF-κB and TGF-β1 signaling pathways, reducing pro-inflammatory cytokines such as TNF-α and IL-1β, and limiting collagen deposition.¹,⁶,¹¹ Overall, these mechanisms support roles in cytoprotection, angiogenesis, and fibrosis regulation in preclinical models of tissue injury.³,⁶